Home - Melanoma Research Alliance

When Astrophysics & Melanoma Collide

Dr. Janis taube, a dermatopathologist at Johns Hopkins University, is using lessons, processes, and tools from the field of astrophysics to approach melanoma in all new ways to better predict treatment outcomes.
Learn More
Connecting the Dots: MRA’s 2017-2018 Annual Report

Since its founding in 2007, the Melanoma Research Alliance (MRA) has become the largest non-profit funder of melanoma worldwide. Since 2007, MRA has directly funded more than $101 million in grants and leveraged an additional $101 million from outside sources to support 266 research projects.

These investments are unparalleled and have helped to transform the landscape for patients and their families.
Read the Report
Improving the Lives of Melanoma Survivors

Melanoma survivors are at a 9-fold increased risk of developing another melanoma. Fortunately, in Dr. Rachel Vogel’s previous research, she found that most melanoma survivors adopt vigilant sun safe behaviors to mitigate this increased risk. Unfortunately, while most survivors adopt safer behaviors, 20% of survivors reported a sunburn in the past year and 10% intentionally went outside for a tan – both strong predictors of inappropriate sun exposure. She hopes to disrupt this cycle and to help melanoma survivors live better.
Read More
Older Patients Do Better on Immunotherapy

Many try to ignore it, some fight it, and others embrace it, but whatever your strategy – aging is an inescapable fact of life. We get wrinkles and lose muscle mass, cognition starts to decline, and our hair starts to grey or fall out – aging marks all of us in ways both visible and not. Dr. Ashani T. Weeraratna was shocked to discover that older melanoma patients had better outcomes than their younger counterparts when treated with immunotherapy.
Read More
Ipilimumab Cured Him, Now He’s Committed to Paying it Forward

Dan needed a miracle. At this point, he’d had six surgeries on his neck, endured radiation therapy, and been enrolled in five clinical trials. Dan’s miracle came in 2006 in the form of an experimental drug, ipilimumab or anti-CTLA4 antibody, that would later be named Yervoy.
Read Dan's Story

Find a Clinical Trial
Get Connected

Scientific Report
Get Involved
About MRA

What's New

11/01/2018 – Connecting the Dots: MRA’s 2017-2018 Annual Report

10/04/2018 – Melanoma Research Alliance Appoints Marc Hurlbert, Ph.D. Chief Science Officer

10/01/2018 – Melanoma Research Alliance Applauds Jim Allison for Nobel Prize in Medicine

09/20/2018 – The Melanoma Research Alliance (MRA) and the Melanoma Research Foundation (MRF) Commend the House and Senate Appropriations Committees for Including $10 Million in Dedicated Funding for Melanoma Research in the FY19 Defense Appropriations Bill.

08/06/2018 – MRA 2018-2019 Request for Proposals Now Available

MRA would like to thank our 2018 Retreat Sponsors